Colorectal cancer (CRC) patients with liver metastases usually obtain less benefit from
immunotherapy, and the underlying mechanisms remain understudied. Here, we identify …

How cancer cells evade the therapeutic effects of immune checkpoint blockade is largely
unknown. Here, we report that fibrinogen-like protein 1 (FGL1), a newly identified immune …

Colorectal cancer (CRC) represents the third most common malignancy and the second
leading cause of cancer-related deaths worldwide. Although immunotherapy has taken …

Liver metastasis is the main cause of death in patients with colorectal cancer (CRC); thus,
necessitating effective biomarkers and therapeutic targets for colorectal cancer liver …

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory
pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death …

Although distant metastases account for most of the deaths in cancer patients, fundamental
questions regarding mechanisms that promote or inhibit metastasis remain unanswered. We …

Objective Solid tumours respond poorly to immune checkpoint inhibitor (ICI) therapies. One
major therapeutic obstacle is the immunosuppressive tumour microenvironment (TME) …

Immune checkpoint blockade is considered a breakthrough in cancer treatment. However,
with the low response rates and therapeutic resistance of patients with hepatocellular …

The immunosuppressive microenvironment plays an important role in tumor progression
and immunotherapy responses. Golgi membrane protein 1 (GOLM1) is correlated to …

Most cases of hepatocellular carcinoma (HCC) arise with the fibrotic microenvironment
where hepatic stellate cells (HSCs) and carcinoma-associated fibroblasts (CAFs) are critical …